SCHEMBL4434050

SCHEMBL4434050

Cc1ccccc1C(c1ccccc1C)n1cccc(C(=O)O)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 2/20 0.41
MAPT P10636 2/20 0.41
MYC P01106 3/20 0.41
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HSD17B10 Q99714 2/20 0.40
HPGD P15428 1/20 0.40
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 2/20 0.39
KMT2A Q03164 2/20 0.39
POLB P06746 1/20 0.38
NR4A1 P22736 1/20 0.37
ALOX15 P16050 1/20 0.37
MEN1 O00255 1/20 0.37
AKR1B10 O60218 1/20 0.37
TRPA1 O75762 1/20 0.37
ABCB11 O95342 1/20 0.37
DHFR P00374 1/20 0.37
LMNA P02545 1/20 0.37
MPO P05164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4436595 0.85 MYC (0.41) MAPTMYCALDH1A1KDM4EHSD17B10
SCHEMBL4987904 0.82 CES2 (0.43) PTGS2MAPTALDH1A1KDM4EHSD17B10
SCHEMBL4427312 0.80 ALDH1A1 (0.43) PTGS2MAPTALDH1A1KDM4EHSD17B10
SCHEMBL4989816 0.77 TTR (0.39) PTGS2MAPTMYCALDH1A1KDM4E
SCHEMBL11634695 0.76 PTGS2 (0.45) PTGS2MAPTMYCALDH1A1KDM4E
SCHEMBL4991582 0.74 POLB (0.42) MAPTALDH1A1KDM4EHSD17B10HPGD
SCHEMBL1137260 0.74 ALDH1A1 (0.48) PTGS2MAPTALDH1A1KDM4EHSD17B10
SCHEMBL2621625 0.74 ALDH1A1 (0.48) PTGS2MAPTALDH1A1KDM4EHSD17B10
SCHEMBL2621624 0.74 ALDH1A1 (0.48) PTGS2MAPTALDH1A1KDM4EHSD17B10
SCHEMBL1944076 0.73 PTGS2 (0.58) PTGS2MAPTALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2125739-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2009-12-02 EP disclosed
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof ENCYSIVE PHARMACEUTICALS, INC. 2008-08-07 US disclosed
WO-2008079371-A1 MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. (US) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188528-A1 Modulators of C3a receptor and methods of use thereof C3AR1, C5, C5AR1 PTGS2 1716/4885MAPT 4654/4885MYC 3967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.